您的位置: 首页 > 2024年5月 第55卷 第5期 > 文字全文
2023年7月 第38卷 第7期11
目录

基于数据挖掘和网络药理学研究中枢性性早熟的用药规律和作用机制

Research on the prescription rules and mechanism of central precocious puberty based on data mining and network pharmacology

来源期刊: 广州医药 | 500-512 发布时间:2024-06-28 收稿时间:2025/11/17 15:49:24 阅读量:37
作者:
关键词:
中枢性性早熟数据挖掘网络药理学高频药对活性成分靶点
central precocious pubertydata miningnetwork pharmacologyhigh-frequency drug pairactive ingredientstargets
DOI:
10.3969/j.issn.1000-8535.2024.05.008
收稿时间:
2023-11-08 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 运用数据挖掘、网络药理学和分子对接的方法,探讨中药复方治疗中枢性性早熟(CPP)的用药规律和作用机制,为其临床治疗提供更多依据。方法 在中国知网(CNKI)、万方数据(Wanfang)、维普中文期刊(VIP)等数据库中检索从建库至2022年10月发表的中药复方治疗CPP的文献,用Excel 2021 收集整理临床治疗CPP的常用中药复方,并通过Excel 2021、SPSS Modeler 18.0、SPSS Statistics 25.0等软件对其进行频次、关联规律等分析,研究CPP治疗的用药规律。在上述基础上采用网络药理学的研究方法,筛选出高频药对的活性成分、作用靶点以及疾病的相关靶点,构建蛋白互作网络,并通过基因本体和京都基因 基因组百科全书通路富集分析来阐明药物的作用机制。最后运用 Autodock Vina 软件进行分子对接对结果验证。结果 共筛选出224篇文献,包含方剂133首,中药188味。发现18味使用超过25次的高频药物;清热类、补虚类的药物应用较多;药物性味以寒及苦为主;归经之中以肝经占比最高;进一步关联分析得到高频药对14个;核心处方4个。网络药理学结果显示,共得到44个活性成分、200个药物靶点、1 287个疾病靶点、70个共有靶点、573条GO富集条目及136条KEGG通路,药物主要成分槲皮素、山奈酚、β-谷甾醇作用于雌激素受体、黄体酮受体等核心靶点,通过内分泌抵抗、雌激素等信号通路发挥治疗作用。分子对接结果显示药物主要活性成分与相应核心靶点具有较好的结合能力。结论 中药复方治疗CPP多为滋阴清热、补虚类药物,与药性寒,药味苦、甘,归肝、肾经的药物配伍使用。其中高频药对“知母-黄柏”通过多成分、多靶点调控内分泌抵抗、雌激素信号通路发挥治疗作用。
Objective To explore the prescription rules and mechanism of traditional Chinese medicine(TCM) in the treatment of central precocious puberty(CPP)by using data mining,network pharmacology and molecular docking,so as to provide more evidence for clinical treatment.Methods Using the literature on the treatment of CPP with TCM compounds,which was retrieved from the databases of CNKI,Wanfang,VIP and other databases from the establishment of the database to October 2022 as the data sources.Excel 2021 was used to collect and summarize the commonly used TCM prescriptions for CPP,and conducted frequency analysis and association rules analysis of CPP by Excel 2021,SPSS Modeler 18.0,SPSS Statistics 25.0 and other software,so as to study the composition rule of prescriptions for CPP.On the basis of these results,network pharmacology method was used to screen out the active ingredients and action targets of high-frequency drugs,and then screen out the disease related targets to construct PPI network.Mechanism of drugs was clarified through GO and KEGG pathway enrichment analysis.Finally,the molecular docking of autodock Vina(Vina)platform was used to verify the results.Results A total of 244 documents met the search criteria,including 133 prescriptions and 188 traditional Chinese medicines.It had been found that 18 high-frequency Chinese medicines were used more than 25 times.The drugs mainly focused on clearing heat and supplementing deficiency.The medicinal flavors were mainly cold and bitter,which belonged to the liver channel.Further correlation analysis yielded 14 high-frequency drug pairs and 4 core prescriptions.The results of network pharmacological analysis showed that 44 active components,200 drug targets,1 287 disease corresponding targets,70 common targets,573 GO enrichment entries and 136 KEGG pathways targets were obtained.It has been found that the main components of the drugs,such as quercetin,kaempferol and β-sitosterol,act on the core targets of ESR1,PGR and play a therapeutic role through endocrine resistance and estrogen signaling pathways.Finally,molecular docking results showed that the main active ingredients of the drug had good binding ability with the corresponding core targets.Conclusions In the treatment of CPP,traditional Chinese medicine is mainly used types of nourish Yin,clear heat and replenish deficiency,which is compatible with the drugs with cold properties,bitter and pliant taste,and the liver and spleen channels.Among them,high-frequency drug pair “ZhiMu-HuangBai” play a therapeutic role in the regulation of endocrine resistance and estrogen signaling pathways through multi-components and multi-targets.
1、 LIU Z,FAN H Y,WANG Y,et al.Targeted disruption of Mapk14(p38MAPK α)in granulosa cells and cumulus cells causes cell-specific changes in gene expression profiles that rescue COC expansion and maintain fertility[J].Mol Endocrinol,2010,24(9):1794-1804. LIU Z,FAN H Y,WANG Y,et al.Targeted disruption of Mapk14(p38MAPK α)in granulosa cells and cumulus cells causes cell-specific changes in gene expression profiles that rescue COC expansion and maintain fertility[J].Mol Endocrinol,2010,24(9):1794-1804.
2、 FARKHONDEH T,MEHRPOUR O,BUHRMANN C,et al.Organophosphorus compounds and MAPK signaling pathways[J].Int J Mol Sci,2020,21(12):4258. FARKHONDEH T,MEHRPOUR O,BUHRMANN C,et al.Organophosphorus compounds and MAPK signaling pathways[J].Int J Mol Sci,2020,21(12):4258.
3、 CHEN L,ZHANG B Y,FENG G D,et al.The mechanism of miRNA-mediated PGR signaling pathway in regulating female reproduction[J].Yi Chuan,2016,38(1):40-51. CHEN L,ZHANG B Y,FENG G D,et al.The mechanism of miRNA-mediated PGR signaling pathway in regulating female reproduction[J].Yi Chuan,2016,38(1):40-51.
4、 AKISON L K,ROBKER R L.The critical roles of progesterone receptor(PGR)in ovulation,oocyte developmental competence and oviductal transport in mammalian reproduction[J].Reprod Domest Anim,2012,47(Suppl 4):288-296. AKISON L K,ROBKER R L.The critical roles of progesterone receptor(PGR)in ovulation,oocyte developmental competence and oviductal transport in mammalian reproduction[J].Reprod Domest Anim,2012,47(Suppl 4):288-296.
5、 DANG X,ZHU Q,HE Y,et al.IL-1β upregulates StAR and progesterone production through the ERK1/2-and p38-mediated CREB signaling pathways in human granulosa-lutein cells[J].Endocrinology,2017,158(10):3281-3291. DANG X,ZHU Q,HE Y,et al.IL-1β upregulates StAR and progesterone production through the ERK1/2-and p38-mediated CREB signaling pathways in human granulosa-lutein cells[J].Endocrinology,2017,158(10):3281-3291.
6、 PAN K,LU Y,CAO D,et al.Long non-coding RNA SNHG1 suppresses the osteogenic differentiation of bone marrow mesenchymal stem cells by binding with HMGB1[J].Biochem Genet,2023:1-15. PAN K,LU Y,CAO D,et al.Long non-coding RNA SNHG1 suppresses the osteogenic differentiation of bone marrow mesenchymal stem cells by binding with HMGB1[J].Biochem Genet,2023:1-15.
7、 KLIMCZAK S,?LIWI?SKA A.Epigenetic regulation of inflammation in insulin resistance[J].Semin Cell Dev Biol,2024(154):185-192. KLIMCZAK S,?LIWI?SKA A.Epigenetic regulation of inflammation in insulin resistance[J].Semin Cell Dev Biol,2024(154):185-192.
8、 NITTA Y,MURAOKA-HIRAYAMA S,SAKURAI K.Catalase is required for peroxisome maintenance during adipogenesis[J].Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(8):158726. NITTA Y,MURAOKA-HIRAYAMA S,SAKURAI K.Catalase is required for peroxisome maintenance during adipogenesis[J].Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(8):158726.
9、 ELLIOT S J,CATANUTO P,PEREIRA-SIMON S,et al.Catalase,a therapeutic target in the reversal of estrogen-mediated aging[J].Mol Ther,2022,30(2):947-962. ELLIOT S J,CATANUTO P,PEREIRA-SIMON S,et al.Catalase,a therapeutic target in the reversal of estrogen-mediated aging[J].Mol Ther,2022,30(2):947-962.
10、 HU Q,HONG L,NIE M,et al.The effect of dehydroepiandrosterone supplementation on ovarian response is associated with androgen receptor in diminished ovarian reserve women[J].J Ovarian Res,2017,10(1):32. HU Q,HONG L,NIE M,et al.The effect of dehydroepiandrosterone supplementation on ovarian response is associated with androgen receptor in diminished ovarian reserve women[J].J Ovarian Res,2017,10(1):32.
11、 曾洲榆,胡力,官燕飞,等.多囊卵巢综合征患者性激素水平与胰岛素抵抗关系[J].广州医药,2022,53(2):31-34. 曾洲榆,胡力,官燕飞,等.多囊卵巢综合征患者性激素水平与胰岛素抵抗关系[J].广州医药,2022,53(2):31-34.
12、 O’HARA L,SMITH L B.Androgen receptor roles in spermatogenesis and infertility[J].Best Pract Res Clin Endocrinol Metab,2015,29(4):595-605. O’HARA L,SMITH L B.Androgen receptor roles in spermatogenesis and infertility[J].Best Pract Res Clin Endocrinol Metab,2015,29(4):595-605.
13、 乔丽丽,蔡德培.滋阴泻火中药对青春期大鼠子宫与卵巢ER、IGF-Ⅰ、AR基因及蛋白表达的影响[J].上海中医药大学学报,2009,23(5):62-65. 乔丽丽,蔡德培.滋阴泻火中药对青春期大鼠子宫与卵巢ER、IGF-Ⅰ、AR基因及蛋白表达的影响[J].上海中医药大学学报,2009,23(5):62-65.
14、 XU X L,DENG S L,LIAN Z X,et al.Estrogen receptors in polycystic ovary syndrome[J].Cells,2021,10(2):459. XU X L,DENG S L,LIAN Z X,et al.Estrogen receptors in polycystic ovary syndrome[J].Cells,2021,10(2):459.
15、 柯江维,杨玉,段荣,等.雌激素受体基因多态性与女孩性早熟关系的研究[J].江西医学院学报,2009,49(7):28-33. 柯江维,杨玉,段荣,等.雌激素受体基因多态性与女孩性早熟关系的研究[J].江西医学院学报,2009,49(7):28-33.
16、 BABU S,JAYARAMAN S.An update on β-sitosterol:A potential herbal nutraceutical for diabetic management[J].Biomed Pharmacother,2020(131):110702. BABU S,JAYARAMAN S.An update on β-sitosterol:A potential herbal nutraceutical for diabetic management[J].Biomed Pharmacother,2020(131):110702.
17、 YU Y,CAO Y,HUANG W,et al.β-Sitosterol ameliorates endometrium receptivity in PCOS-like mice:The mediation of gut microbiota[J].Front Nutr,2021(8):667130. YU Y,CAO Y,HUANG W,et al.β-Sitosterol ameliorates endometrium receptivity in PCOS-like mice:The mediation of gut microbiota[J].Front Nutr,2021(8):667130.
18、 WONG S K,CHIN K Y,IMA-NIRWANA S.The osteoprotective effects of kaempferol:The evidence from in vivo and in vitro studies[J].Drug Des Devel Ther,2019(13):3497-3514. WONG S K,CHIN K Y,IMA-NIRWANA S.The osteoprotective effects of kaempferol:The evidence from in vivo and in vitro studies[J].Drug Des Devel Ther,2019(13):3497-3514.
19、 YANG Y,CHEN Z,ZHAO X,et al.Mechanisms of Kaempferol in the treatment of diabetes:A comprehensive and latest review[J].Front Endocrinol,2022(13):990299. YANG Y,CHEN Z,ZHAO X,et al.Mechanisms of Kaempferol in the treatment of diabetes:A comprehensive and latest review[J].Front Endocrinol,2022(13):990299.
20、 MA C,XIANG Q,SONG G,et al.Quercetin and polycystic ovary syndrome[J].Front Pharmacol,2022(13):1006678. MA C,XIANG Q,SONG G,et al.Quercetin and polycystic ovary syndrome[J].Front Pharmacol,2022(13):1006678.
21、 赵倩,霍宇,姜蔚.知柏地黄丸的药理作用和临床应用研究进展[J].中国医药,2022,17(11):1752-1756. 赵倩,霍宇,姜蔚.知柏地黄丸的药理作用和临床应用研究进展[J].中国医药,2022,17(11):1752-1756.
22、 范顺明,张春玲,王佳琪,等.知母-黄柏药对盐炙前后配伍对2型糖尿病大鼠糖脂代谢的影响[J].中国实验方剂学杂志,2021,27(3):22-29. 范顺明,张春玲,王佳琪,等.知母-黄柏药对盐炙前后配伍对2型糖尿病大鼠糖脂代谢的影响[J].中国实验方剂学杂志,2021,27(3):22-29.
23、 郭金鑫,卢昱,刘改燕,等.儿童超重肥胖与中枢性性早熟关系的病例对照研究[J].中国妇幼健康研究,2023,34(3):1-5. 郭金鑫,卢昱,刘改燕,等.儿童超重肥胖与中枢性性早熟关系的病例对照研究[J].中国妇幼健康研究,2023,34(3):1-5.
24、 兰宝恒,吴泽青.柴胡的化学成分及药理作用研究进展[J].新乡医学院学报,2023,40(2):174-180. 兰宝恒,吴泽青.柴胡的化学成分及药理作用研究进展[J].新乡医学院学报,2023,40(2):174-180.
25、 白浩东,张子东,苏慧琳,等.炮制对知母化学成分及药理作用影响的研究进展[J].中国药房,2021,32(17):2159-2163. 白浩东,张子东,苏慧琳,等.炮制对知母化学成分及药理作用影响的研究进展[J].中国药房,2021,32(17):2159-2163.
26、 王玲,杜潇,祝华莲,等.黄柏有效成分的药理作用研究进展[J].江苏中医药,2022,54(4):77-81. 王玲,杜潇,祝华莲,等.黄柏有效成分的药理作用研究进展[J].江苏中医药,2022,54(4):77-81.
27、 陈金鹏,张克霞,刘毅,等.地黄化学成分和药理作用的研究进展[J].中草药,2021,52(6):1772-1784. 陈金鹏,张克霞,刘毅,等.地黄化学成分和药理作用的研究进展[J].中草药,2021,52(6):1772-1784.
28、 尚红艳,党慧敏,刘润侠,等.刘润侠教授治疗女童特发性中枢性性早熟临证经验[J].光明中医,2022,37(22):4045-4049. 尚红艳,党慧敏,刘润侠,等.刘润侠教授治疗女童特发性中枢性性早熟临证经验[J].光明中医,2022,37(22):4045-4049.
29、 李全红,郭品,田靖,等.儿童性早熟长期GnRHa治疗问题的哲学思辨[J].医学与哲学,2020,41(1):18-20,57. 李全红,郭品,田靖,等.儿童性早熟长期GnRHa治疗问题的哲学思辨[J].医学与哲学,2020,41(1):18-20,57.
30、 陈莹,全会标,王斐.中枢性性早熟的发病因素及相关治疗方法应用研究进展[J].山东医药,2022,62(36):105-108. 陈莹,全会标,王斐.中枢性性早熟的发病因素及相关治疗方法应用研究进展[J].山东医药,2022,62(36):105-108.
31、 倪娜,苏恒,孔祥阳.浅谈中枢性性早熟的发病机制[J].中国生物化学与分子生物学报,2021,37(6):727-732. 倪娜,苏恒,孔祥阳.浅谈中枢性性早熟的发病机制[J].中国生物化学与分子生物学报,2021,37(6):727-732.
32、 崔威,文洁珍.文洁珍治疗岭南地区儿童特发性性早熟经验浅谈[J].湖南中医药大学学报,2017,37(3):291-293. 崔威,文洁珍.文洁珍治疗岭南地区儿童特发性性早熟经验浅谈[J].湖南中医药大学学报,2017,37(3):291-293.
33、 李堂,徐爱晶.儿童性早熟[J].中国儿童保健杂志,2010,18(12):930-933. 李堂,徐爱晶.儿童性早熟[J].中国儿童保健杂志,2010,18(12):930-933.
34、 周静茹,杨芳,刘彦君,等.中枢性性早熟儿童心理社会状态的范围综述[J].中国性科学,2023,32(4):143-147. 周静茹,杨芳,刘彦君,等.中枢性性早熟儿童心理社会状态的范围综述[J].中国性科学,2023,32(4):143-147.
35、 SHI L,JIANG Z,ZHANG L.Childhood obesity and central precocious puberty[J].Front Endocrinol,2022(13):1056871. SHI L,JIANG Z,ZHANG L.Childhood obesity and central precocious puberty[J].Front Endocrinol,2022(13):1056871.
36、 中华医学会儿科学分会内分泌遗传代谢学组,《中华儿科杂志》编辑委员会.中枢性性早熟诊断与治疗共识(2015)[J].中华儿科杂志,2015,53(6):412-418. 中华医学会儿科学分会内分泌遗传代谢学组,《中华儿科杂志》编辑委员会.中枢性性早熟诊断与治疗共识(2015)[J].中华儿科杂志,2015,53(6):412-418.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录